期刊文献+

他汀类药物与细胞增殖性心血管疾病的关系的研究现状 被引量:5

下载PDF
导出
摘要 作者综述了他汀类药物的作用及其机制 ,重点概述了它与高血压病、动脉粥样硬化和经皮腔内冠状动脉成形术后再狭窄的关系。
出处 《心脏杂志》 CAS 2002年第2期162-164,共3页 Chinese Heart Journal
  • 相关文献

参考文献11

  • 1[1]Negre-aminou P,Vliet AK,Erck M,et al.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types[J].Biochem Biophys Acta,1997,1345: 259-268.
  • 2[2]Jiang J,Roman RJ.Lovastatin prevents development of hypertension in spontaneously hypertensive rats [J].Hypertension,1997,30:968-974.
  • 3[3]Laufs U,Marra D,Node K,et al.3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of P27kip1 [J].J Bio Chem,1999,274:21926-21931.
  • 4[4]Guijarro C,Blanco-Colio LM,Ortego M,et al.3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture [J].Circ Res,1998,83:490-500.
  • 5[5]Kano H,Hayashi T,Sumi D,et al.A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO Synthase mRNA [J].Biochem Biophys Res Commu,1999,259:414-419.
  • 6[6]Bellosta S,Via D,Canavesi M,et al.HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages[J].Arterioscle Thromb Vasc Biol,1998,18:1671-1678.
  • 7[7]Vrtovsnik F,Couettes,Prie D,et al.Lovastatin inhibition of renal epithelial tubular cell proliferation involves a P21ras activated AP-1-dependent pathway[J].Kidney Int,1997,52:1016-1027.
  • 8[8]Narisawa J,Morotomi M,Fukaura Y,et al.Chemoprevention by HMG-CoA reductase inhibitor of N-methyl-N-nitrosoureg induced colon carcinogenesis in F344 Rats[J].Jpn J Cancer Res,1996,87:798-804.
  • 9[9]Bellosta S,Bernini F,Ferri N,et al.Direct vascular effects of HMG-CoA reductase inhibitor[J].Atherosclerosis,1998,137:s101-s109.
  • 10[10]Corsini A,Pazzucconi F,Arnaboldi L,et al.Direct of Effects of statins on the Vascular Wall [J].J Cardiovasc Pharmacol,1998,31:773-778.

同被引文献40

  • 1SU S F,HSIAO C L,CHU C W, et al. Effects of pravastatin on ventricular mass in patients with hyperlipidemia and essential hypertension[J]. Am J Cardiol, 2000,86(5):514-518.
  • 2BACHENBERG T C, SHUB C, HAUCK A J, et al. Can anatomical left ventricular mass be estimated reliably by Mmode echocardiography? A clinic pathological study of 93 patients[J]. Echocardiography, 1991,8(1):9-15.
  • 3HAMMOND I W, DEVEREUX R B, ALDERMAN M H,et al. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adult[J]. J Am Coil Cardiol, 1998,12(4):996-1004.
  • 4OLIVETTI G, CIGOLA E, MAESTRI R, et al. Recent advances in cardiac hypertrophy[J]. Cardiovasc Res, 2000,45(1):68-75.
  • 5BELL J P, MOSFER S I, LANG D, et al. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs[J]3. Am J Physiol Heart Circ Physiol,2001,281(4):H1704-H1710.
  • 6SUNG J, OUYANG P, BACHER A C, et al. Peripheral endothelium-dependent flow-mediated vasodilatation is associated with left ventricular mass in older persons with hypertention[J]. Am Heart J, 2002,144(1): 39-44.
  • 7KREUZER J, WATSON L, HERDEGEN T, et al. Effects of HMG-CoA reductase inhibition on PDGF and angiotension Ⅱ-mediated transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro[J]. Eur J Med Res, 1999,4(4):135-143.
  • 8Franz HM, Reinhard K. Left ventricular hypertrophy: a pressure independent cardiovascular risk factor[J].J Cardiovasc Pharmacol,1993,22(suppl 1): S7-S13.
  • 9Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG-CoA reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease[J].Cardiovasc Res,2001,49(2):281-287.
  • 10Weber KT. Fibrosis and hypertensive heart disease[J].Curr Opin Cardiol,2000,15(4):264-272.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部